Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenetic therapy for B-cell malignancies.

Seminars in oncology - 1 Dec 2000

Kipps T J, Chu P, Wierda W G

Abstract excerpt

Neoplastic B cells are stealthlike in their ability to evade immune detection, even by allogeneic T cells of normal healthy donors. This stealthlike phenotype can be reversed by activating neoplastic B cells through ligation of CD40, a cell surface molecule that can interact with a ligand expressed on activated T cells. The gene encoding this ligand, CD154, can be transferred into neoplastic B cells ex vivo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to B-Lymphocytes
Share to CD40 Ligand

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Transfer Techniques

Share to Genetic Therapy

Share to Hematologic Neoplasms

Share to Immunogenetics

Share to Maximum Tolerated Dose

Source

Identifiers

PMID: 11225994

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenetic therapy for B-cell malignancies.PMID 11225994Read ↗

Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.Semantic proximity Read ↗

Prospect of Targeting the CD40 Pathway for Cancer TherapySemantic proximity Read ↗

A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.Semantic proximity Read ↗

A novel immunogene therapy to cancer with high tumor selectivity and safetySemantic proximity Read ↗

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1Semantic proximity Read ↗

Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 MoleculeSemantic proximity Read ↗

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignanciesSemantic proximity Read ↗

Immunotherapeutic strategies for EBV-associated malignancies.Semantic proximity Read ↗

A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapySemantic proximity Read ↗

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.Semantic proximity Read ↗

Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivoSemantic proximity Read ↗

Targeting cancer with bispecific antibodies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.